ArticleFrontiers in neuroscience2025
Electroacupuncture exerts neuroprotective effects and alters gut microbiota in a MPTP-induced mouse model of Parkinson's disease.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the therapeutic mechanism of electroacupuncture (EA) in a mouse model of Parkinson's disease (PD) induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Methods: Motor functions were evaluated using open field test and pole tests. Tyrosine hydroxylase (TH) expression in the substantia nigra and striatum was detected by immunohistochemistry. Intestinal barrier integrity was assessed via immunofluorescence staining of tight junction proteins ZO-1 and Occludin. Gut microbiota composition was analyzed by 16S rRNA sequencing. Results: EA treatment significantly improved motor deficits, restored TH expression in nigrostriatal regions, and enhanced colonic ZO-1 and Occludin levels. EA reversed MPTP-induced dysbiosis, notably normalizing the abundances of Dubosiella, Lactobacillus, Enterococcus, Desulfovibrio, Bacteroides, Allobaculum, and Parasutterella. Microbial co-occurrence network analysis revealed that EA simplified hyperconnected interactions and improved network stability. Conclusion: EA treatment attenuated PD progression, which was associated with the remodeling of gut microbiota structure and restoration of microbial network stability. The concomitant protection of dopaminergic function suggests a potential link mediated by the gut-brain axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.